272 related articles for article (PubMed ID: 25751241)
1. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
[TBL] [Abstract][Full Text] [Related]
3. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
[TBL] [Abstract][Full Text] [Related]
4. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
[TBL] [Abstract][Full Text] [Related]
5. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
Dupuis-Girod S; Ambrun A; Decullier E; Fargeton AE; Roux A; Bréant V; Colombet B; Rivière S; Cartier C; Lacombe P; Chinet T; Blivet S; Blondel JH; Gilbert-Dussardier B; Dufour X; Michel J; Harle JR; Dessi P; Faure F
JAMA; 2016 Sep; 316(9):934-42. PubMed ID: 27599328
[TBL] [Abstract][Full Text] [Related]
6. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
7. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
[TBL] [Abstract][Full Text] [Related]
8. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
Epperla N; Hocking W
Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
[TBL] [Abstract][Full Text] [Related]
9. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L
Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613
[TBL] [Abstract][Full Text] [Related]
10. Intranasal bevacizumab injections improve quality of life in HHT patients.
Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.
Karnezis TT; Davidson TM
Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
[TBL] [Abstract][Full Text] [Related]
14. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
Fleagle JM; Bobba RK; Kardinal CG; Freter CE
Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
[TBL] [Abstract][Full Text] [Related]
15. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
[TBL] [Abstract][Full Text] [Related]
16. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Chen S; Karnezis T; Davidson TM
Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
[TBL] [Abstract][Full Text] [Related]
17. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
Khoueir N; Borsik M; Camous D; Herman P; Verillaud B
Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760
[TBL] [Abstract][Full Text] [Related]
18. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F
MAbs; 2014; 6(3):794-9. PubMed ID: 24481211
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
Parambil JG; Woodard TD; Koc ON
Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
[TBL] [Abstract][Full Text] [Related]
20. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding.
Iyer VN; Apala DR; Pannu BS; Kotecha A; Brinjikji W; Leise MD; Kamath PS; Misra S; Begna KH; Cartin-Ceba R; DuBrock HM; Krowka MJ; O'Brien EK; Pruthi RK; Schroeder DR; Swanson KL
Mayo Clin Proc; 2018 Feb; 93(2):155-166. PubMed ID: 29395350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
